Literature DB >> 9643284

Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

D G Evans1, L Trueman, A Wallace, S Collins, T Strachan.   

Abstract

Blood samples from 125 unrelated families with classical type 2 neurofibromatosis (NF2) with bilateral vestibular schwannomas have been analysed for mutations in the NF2 gene. A further 17 families fulfilling modified criteria for NF2 have also been analysed. Causative mutations have been identified in 54 (43%) classical families and six (35%) of those fulfilling modified criteria. Forty-two cases from 38 families with truncating mutations had an average age at onset of symptoms of 19 years and diagnosis at 22.4 years. Fifty-one cases from 16 families with splice site mutations (15 from six), missense mutations (18 from six), and large deletions (18 from five) had an average age of onset of 27.8 years and at diagnosis of 33.4 years. Subjects with truncating mutations were significantly more likely to have symptoms before 20 years of age (p<0.001) and to develop at least two symptomatic CNS tumours in addition to vestibular schwannoma before 30 years (p<0.001). There were also significantly fewer multigenerational families with truncating mutations. Four further truncating mutations were in mosaic form and were associated with milder disease than other similar mutations. This large study has confirmed the previous impression that truncating mutations are associated with severe disease, but caution has to be exercised in using mutation type to predict disease course.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9643284      PMCID: PMC1051337          DOI: 10.1136/jmg.35.6.450

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  24 in total

1.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

2.  Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes.

Authors:  L Kluwe; S Bayer; M E Baser; W Hazim; W Haase; C Fünsterer; V F Mautner
Journal:  Hum Genet       Date:  1996-11       Impact factor: 4.132

3.  Eleven novel mutations in the NF2 tumour suppressor gene.

Authors:  D Bourn; G Evans; S Mason; S Tekes; L Trueman; T Strachan
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

4.  Highly polymorphic dinucleotide repeat at the NF2 gene.

Authors:  D Bourn; T Strachan
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

Review 5.  Schwannomatosis: a clinical and pathologic study.

Authors:  M MacCollin; W Woodfin; D Kronn; M P Short
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

6.  Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.

Authors:  D M Parry; M M MacCollin; M I Kaiser-Kupfer; K Pulaski; H S Nicholson; M Bolesta; R Eldridge; J F Gusella
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

7.  Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.

Authors:  M H Ruttledge; A A Andermann; C M Phelan; J O Claudio; F Y Han; N Chretien; S Rangaratnam; M MacCollin; P Short; D Parry; V Michels; V M Riccardi; R Weksberg; K Kitamura; J M Bradburn; B D Hall; P Propping; G A Rouleau
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

8.  Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.

Authors:  E K Bijlsma; A J Wallace; D G Evans
Journal:  J Med Genet       Date:  1997-11       Impact factor: 6.318

9.  Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study.

Authors:  D G Evans; S Mason; S M Huson; M Ponder; A E Harding; T Strachan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

10.  Diagnostic issues in a family with late onset type 2 neurofibromatosis.

Authors:  D G Evans; D Bourn; A Wallace; R T Ramsden; J D Mitchell; T Strachan
Journal:  J Med Genet       Date:  1995-06       Impact factor: 6.318

View more
  42 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.

Authors:  Anne-Marie Bashour; J-J Meng; Wallace Ip; Mia MacCollin; Nancy Ratner
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

Review 4.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

5.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

6.  Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection.

Authors:  Kiran K Mantripragada; Patrick G Buckley; Caroline Jarbo; Uwe Menzel; Jan P Dumanski
Journal:  J Mol Med (Berl)       Date:  2003-06-27       Impact factor: 4.599

7.  Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Zhi-Hai Peng; Fang Zhang; Guo-Qiang Qiu; Lin He
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

8.  Patched homolog 1 gene mutation (p.G1093R) induces nevoid basal cell carcinoma syndrome and non-syndromic keratocystic odontogenic tumors: A case report.

Authors:  Giovanni Ponti; Annamaria Pollio; Lorenza Pastorino; Giovanni Pellacani; Cristina Magnoni; Sabina Nasti; Giulio Fortuna; Aldo Tomasi; Giovanna Bianchi Scarrà; Stefania Seidenari
Journal:  Oncol Lett       Date:  2012-05-08       Impact factor: 2.967

9.  Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.

Authors:  Mikołaj Łaniewski-Wołłk; Monika Gos; Andrzej Koziarski; Agnieszka Szpecht-Potocka
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.